相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
Marius Bill et al.
BLOOD ADVANCES (2023)
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Luca Vincenzo Cappelli et al.
LEUKEMIA (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
Diego Carbonell et al.
CANCERS (2022)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease
Alex Bataller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Chi Young Ok et al.
HAEMATOLOGICA (2019)
Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML
Evgenii Shumilov et al.
LEUKEMIA & LYMPHOMA (2019)
Analysis of error profiles in deep next-generation sequencing data
Xiaotu Ma et al.
GENOME BIOLOGY (2019)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Lucie Petrova et al.
CLINICAL BIOCHEMISTRY (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
Chiara Brambati et al.
HAEMATOLOGICA (2016)
Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
Chiara Brambati et al.
HAEMATOLOGICA (2016)
Improved Minimal Residual Disease Detection by Targeted Quantitative Polymerase Chain Reaction in Nucleophosmin 1 Type a Mutated Acute Myeloid Leukemia
Louise Pettersson et al.
GENES CHROMOSOMES & CANCER (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Lev M. Kats et al.
CELL STEM CELL (2014)
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse
Max Hubmann et al.
HAEMATOLOGICA (2014)
Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing
Guoli Chen et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia
Hsiao-Wen Kao et al.
NEOPLASIA (2014)
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Jan Kroenke et al.
BLOOD (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene
Ivana Jeziskova et al.
LEUKEMIA & LYMPHOMA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations
Felicitas Thol et al.
GENES CHROMOSOMES & CANCER (2012)
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission
W-C Chou et al.
LEUKEMIA (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Susanne Schnittger et al.
BLOOD (2010)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor
Christina Papadaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
J. Cloos et al.
LEUKEMIA (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia
S Scholl et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2005)
Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays
DA Di Giusto et al.
NUCLEIC ACIDS RESEARCH (2004)
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
KM Murphy et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2003)
分享论文
